The venture capital arm of German chemicals firmEvonik已经投资于内华达州的3D印刷制药公司Laxxon Medical将3D印刷平板电脑的批量生产更接近现实。
The firms are partnering to fabricate novel multi-drug tablets en-masse using Laxxon’s patented 3D screen printing technology and Evonik’s specialized polymer materials. The aim of the partnership is to improve drug delivery for patients while also advancing the commercialization of 3D printed pharmaceuticals.
Evonik医疗保健业务系列负责人Thomas Riermeier说：“药物提供的越来越高，并越来越针对特定的患者群体。”
“与Laxxon的合作将使我们能够在这个重要和新兴市场中加速我们的活动。”
Commercializing 3D printed pharmaceuticals
与传统方法相比greater personalization for individual patients和on-demand delivery of medication。而进度正在3D印刷药品的商业化，在将技术从实验室转变为临床环境中仍然存在挑战。
迄今为止，Aprecia’s3D printed Spritam epilepsy medication is the only one to have获得了FDA批准，，，，although other firms aren’t far behind. For instance, global pharmaceutical firmMerck已经与EOS组公司AMCM到develop and produce 3D printed tablets，，，，initially for clinical trials and then later for commercial manufacturing.
Meanwhile, researchers atUCL，，，，USCandFabRXhave successfully usedvolumetric 3D printing to fabricate drug-loaded tablets在几秒钟内，它的速度明显快于当前为生产药品而部署的3D打印方法。
Evonik and Laxxon’s partnership
Laxxon Medical开发了一种新颖的3D丝网印刷技术，专门针对制造结构化片剂，可以随着时间的推移而受控释放药物。公司的丝网印刷创新药物（SPID）技术允许多种药物成分通过3D打印层组合在一片药丸中。
The 3D screen printing method enables the inner structure of the pill to contain alternative layers of active ingredients and inert layers in order to allow various doses of the drug to be released over time. The technique also permits multiple drugs to be layered on top of each other and in essence combines several pills into one.
One benefit of Laxxon’s screen printing method is its speed, which the firm claims is “significantly faster” than established 3D printing processes and could scale up the fabrication of 3D printed pharmaceuticals to mass production levels.
“This technology is great for patients,” said Bernhard Mohr, head of Evonik Venture Capital. “We expect fewer side effects from a more controlled drug delivery and having fewer pills reduces the risk of forgetting doses during the day.
“We are pleased to support innovation that brings real benefits to people and their health.”
With 60 years experience in drug delivery systems, Evonik makes excipients which are inactive ingredients that serve as the vehicle for a drug, such as polymers that act as a coating for tablets and allow drug release over a sustained period of time.
通过他们的联合产品开发协议，Evonik的产品将用于Laxxon Medical的印刷糊状物，以确保在3D印刷平板电脑中有针对性地递送药物。
The investment from Evonik’s venture capital arm will also see the firm manufacture the 3D printed tablets for Laxxon, of which the size, geometry, inner structure, and materials used combine to allow the ideal speed of chemical reactions in the body for the optimal release of drugs.
“Evonik is the perfect partner to support the development of tablets with unique release properties,” said Helmut Kerschbaumer, Co-founder of Laxxon Medical. “We are happy to have one of the world’s leading specialty chemicals companies with which we can further develop our products and at the same time commercially manufacture them.”
Subscribe to the3D打印行业通讯for the latest news in additive manufacturing. You can also stay connected by following us on推特并喜欢我们Facebook。
Looking for a career in additive manufacturing? Visit3D打印作业在行业中选择一系列角色。
订阅我们YouTube channel最新的3 d打印视频短裤、评论betway必威手机版登录nd webinar replays.
Featured image shows通过Laxxon Medical的SPID技术进行的3D印刷药物。通过Laxxon Medical照片。
